Astellas Pharma Inc (ALPMF PINK) stock market data APIs
$16.563
0(0%)
as of November 2, 2026
Try our APIs with
free plan!
Astellas Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Prev. Close
16.563
Open
16.5669
High
16.574
Low
16.3848
52 wk Range
9.541-17.8
Market Cap
26 895 M
P/E Ratio
11.3636
Shares Outstanding
1 793 M
Revenue
2 274 365 M
EPS
0.4955
Dividends (Yield)
0.0355
Beta
0.046
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
Astellas Pharma Inc Fundamental data includes:
- Net Revenue: 2 274 365 M
- EBITDA: 669 549 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: 18.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology
- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand - - Au...
Pfizer Talzenna/Xtandi combo approved for earlier prostate cancer setting
[Pfizer office entrance with logo on a modern glass building, surrounded by greenery.] Veronique D * The combination of Pfizer's (PFE [https://seekingalpha.com/symbol/PFE]) Talzenna (talazoparib) p...
New Canadian Real-World Evidence at ESMO 2026 Highlights Integration of CLDN18.2 Testing and Targeted Treatment in Clinical Practice
- Canadian patient support program data demonstrate the importance of timely biomarker testing on access to targeted therapy for eligible patients with advanced gastric or gastroesophageal junction ca...
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins will design and develop miniprotein candidates exclusively licensed to Astellas against undisclosed targets, with Astellas responsible for advancing them through commercialization BOSTON,...
Get Astellas Pharma Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.